Clinical Trial Update: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase II open-label trial of everolimus plus letrozole in postmenopausal women with ER+, HER2- metastatic or locally advanced breast cancer completed with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Letrozole (letrozole)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hormone Receptor Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-09